Related Experiment Video
Updated: Jun 6, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
Dapagliflozin: more than just another oral glucose-lowering agent?
Niki Katsiki1, Nikolaos Papanas, Dimitri P Mikhailidis
1Department of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal Free Hospital campus, University College London Medical School, University College London (UCL), London NW3 2QG, UK.
Importance Of The Field:
With current hypoglycemic therapies, only half of type 2 diabetes mellitus (T2DM) patients achieve optimal glycemic control and even fewer maintain it. Therefore, there is an unmet need for novel antidiabetic agents. Dapagliflozin, a selective inhibitor of sodium glucose transporter 2 (SGLT2), targets hyperglycemia independently of insulin, via decreasing renal glucose reabsorption.
Areas Covered In This Review:
We critically assess the results of up-to-date clinical trials with dapagliflozin in patients with T2DM and discuss its potential therapeutic applications.
What The Reader Will Gain:
Dapagliflozin, apart from targeting hyperglycemia, also exerts beneficial effects on blood pressure, lipid profile, body weight and waist circumference. Furthermore, serum uric acid and high sensitivity C-reactive protein levels were decreased in dapagliflozin-treated patients. However, there are also potentially negative effects related to dapagliflozin use that need to be addressed, such as increased hematocrit and serum parathyroid levels and the possibility of a higher rate of urinary tract and genital infections.
Take Home Message:
The use of dapagliflozin in the treatment of T2DM patients seems promising but more evidence is needed.
Related Concept Videos
Oral Hypoglycemic Agents: Glinides
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Sulfonylureas